<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305121</url>
  </required_header>
  <id_info>
    <org_study_id>FR TFNA</org_study_id>
    <nct_id>NCT02305121</nct_id>
  </id_info>
  <brief_title>Focused Registry on the Titanium Trochanter Fixation Nail Advanced (TFNAdvanced™)</brief_title>
  <acronym>FR TFNA</acronym>
  <official_title>A Focused Registry on the Titanium Trochanter Fixation Nail Advanced (TFNAdvanced™) - TFNA System in Patients With Proximal Inter-, Per- or Subtrochanteric Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AO Clinical Investigation and Publishing Documentation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AO Innovation Translation Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is the prospective data collection of a new device used for&#xD;
      trochanteric fractures of the femur. It should be answered how the newly developed implant&#xD;
      called Trochanteric Fixation Nailing with anti-rotation feature (TFNA) is performing&#xD;
      clinically and radiological in terms of intra- and postoperative complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In comparison to previous implants, the TFNA has been improved substantially. Therefore the&#xD;
      purpose of this focused registry is to investigate how the newly developed implant called&#xD;
      Trochanteric Fixation Nailing with anti-rotation feature (TFNA) is performing clinically and&#xD;
      radiologically in terms of surgical technique, intra- and postoperative complications and&#xD;
      short term outcome.&#xD;
&#xD;
      All investigated procedures are part of the standard of care treatment. Only the parker&#xD;
      mobility score is study-specific. All patients included are followed up from the time point&#xD;
      of enrollment until three months after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of mechanical and surgical complications defined as the number of</measure>
    <time_frame>up to 3 months</time_frame>
    <description>cut out and cut through&#xD;
secondary displacement of parts of the implant&#xD;
breakage of the implant&#xD;
iatrogenic fractures&#xD;
surgical revisions&#xD;
acute deep infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OR time</measure>
    <time_frame>Intraoperative</time_frame>
    <description>(in min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fracture classification Classification</measure>
    <time_frame>Baseline</time_frame>
    <description>according to AO/OTA Fracture and Dislocation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parker Mobility Score</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Evaluation of the mobility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of reduction and implant placement</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Based on radiographic analysis with focus on the position of the nail tip relative to the femoral canal and the migration of the head neck element</description>
  </secondary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Pertrochanteric Fractures of Femur</condition>
  <condition>Intertrochanteric Fractures of the Femur</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TFNA</intervention_name>
    <description>All investigated procedures are part of the standard of care treatment. Only the parker mobility score is study-specific. All patients included are followed up from the time point of enrollment until three months after surgery</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with per- or intertrochanteric fractures of the femur, fracture of the&#xD;
        trochanteric area with diaphyseal extension or combined fractures of the trochanteric area&#xD;
        and the femoral shaft.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Pertrochanteric femoral fracture (31-A1 and 31-A2), intertrochanteric fracture&#xD;
             (31-A3), fracture of the trochanteric area (31-A1/A2/A3) with diaphyseal extension or&#xD;
             combined fracture of the trochanteric area and the femoral shaft (32-A/B/C) treated&#xD;
             with the TFNA system according to the technique guide&#xD;
&#xD;
          -  Ability to understand the content of the patient information / informed consent form&#xD;
&#xD;
          -  Willingness and ability to participate in the registry according to the registry plan&#xD;
             (RP)&#xD;
&#xD;
          -  Signed and dated IRB/EC-approved written informed consent or assent from a family&#xD;
             member&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Additional acute fracture&#xD;
&#xD;
          -  Any not medically managed severe systemic disease&#xD;
&#xD;
          -  Recent history of substance abuse (i.e., recreational drugs, alcohol) that would&#xD;
             preclude reliable assessment&#xD;
&#xD;
          -  Pregnancy or women planning to conceive within the registry period&#xD;
&#xD;
          -  Prisoner&#xD;
&#xD;
          -  Participation in any other medical device or medicinal product registry within the&#xD;
             previous month that could influence the results of the present registry&#xD;
&#xD;
          -  Intraoperative decision to use implants other than the devices under investigation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Blauth, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck, Department of Trauma Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trochanteric fracture</keyword>
  <keyword>Nail</keyword>
  <keyword>Fracture reduction</keyword>
  <keyword>Antirotation</keyword>
  <keyword>trochanteric area with diaphyseal extension</keyword>
  <keyword>trochanteric area with femoral shaft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

